What are you looking for?
Switching to aflibercept 8 mg was associated with modest visual gains and improved retinal anatomy in previously treated eyes with neovascular age-related macular degeneration (nAMD), with benefits maintained through 6 months, according to a study. Investigators evaluated outcomes in eyes (N = 300) that were switched to aflibercept 8 mg after prior anti-vascular endothelial growth... ...
A pooled analysis of the Phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume...
The biosimilar aflibercept-ayyh was associated with stable vision in patients who switched from other anti-VEGF therapies and improved vision in treatment-naïve patients,...
Switching to aflibercept 8 mg improved anatomical outcomes and reduced reliance on shorter treatment intervals, according to a study. However, researchers note...
Switching to aflibercept 8 mg was associated with modest visual gains and improved retinal anatomy in previously treated eyes with neovascular age-related macular degeneration (nAMD), with benefits maintained through 6...
A pooled analysis of the Phase 3 PULSAR and PHOTON trials found that aflibercept 8 mg, administered at a higher injection volume than aflibercept 2 mg, was not associated with...
The biosimilar aflibercept-ayyh was associated with stable vision in patients who switched from other anti-VEGF therapies and improved vision in treatment-naïve patients, according to a real-world analysis. The analysis included... ...
Switching to aflibercept 8 mg improved anatomical outcomes and reduced reliance on shorter treatment intervals, according to a study. However, researchers note that an observed decline in visual acuity warrants...
Intravitreal aflibercept 8 mg administered with a loading phase followed by a treat-and-extend regimen improved visual acuity and reduced retinal and choroidal thickness over 1 year in patients with treatment-naïve...
Patients with age-related macular degeneration (AMD) were found to have a higher risk of developing several mental health disorders, including depression, anxiety, self-harm, and psychosis, according to a study. The...
Alternative aflibercept dosing regimens for wet age-related macular degeneration (AMD) may reduce treatment burden without compromising efficacy, according to a study. Investigators found that treat-and-extend (TAE) and pro re nata...
In this episode of The Ophthalmic Project, host Mark Dlugoss and guest Sam Barone, MD, discuss Nanoscope Therapeutics’ new optogenetic therapy to help restore vision in patients with retinal diseases...